Project Grant R01CA311131
Award Date 6/1/26
Completion Date 5/30/31
Dollars Obligated $533K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
- Grant Award Summary Cincinnati Children's Hospital Medical Center received a $530,106 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded September 11, 2025, with completion by August 31, 2030. The research project targets polyamine metabolism in leukemia stem cells (LSCs) to develop therapeutic interventions for acute myeloid leukemia (AML). The project delivers fundamental research investigating the mechanistic role of...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $683,698 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026 through May 31, 2031. The award supports research to develop and validate a novel therapeutic strategy for treating high-risk B-cell acute lymphoblastic leukemia (B-ALL), particularly in relapsed/refractory cases and those resistant to anti-CD19 therapy. The primary...
- This $683,472 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Cincinnati to develop a novel targeted therapy for acute myeloid leukemia (AML). The key objectives are to therapeutically target the DHODH enzyme to induce AML cell differentiation, activate the immune system, and induce ferroptosis-mediated cell death. This approach aims to better differentiate AML cells from normal hematopoietic stem cells and enhance...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Cincinnati Children's Hospital Medical Center a $1.48M Project Grant on September 1, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and evaluate SUMMIT (Supporting Medication Management with Individualized Treatment), a tailored medication adherence-promotion intervention designed specifically for adolescents and young adults (AYAs) with cancer. The five-year award, extending through...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $586,364 Project Grant to the University of California, Irvine on April 7, 2026, under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on Type 1 Innate Lymphoid Cells (ILC1s) and their potential therapeutic applications against acute myeloid leukemia (AML). The research will be conducted through March 31, 2031, and focuses on elucidating the mechanisms by which ILC1s target and...
- Federal Grant Award Summary Baylor College of Medicine received a $160,500 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective July 10, 2025, with completion targeted for June 30, 2027. The award funds the development and investigation of in vivo murine models to examine the role of caspase-2 in nucleophosmin-mutated acute myeloid leukemia (NPM1C+ AML). The research deliverables include the establishment of transgenic mouse...
- Federal Grant Award Summary The National Cancer Institute awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) a $3.48 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. This project systematically identifies genomic heterogeneity and relapse predictors in pediatric and adolescent/young adult patients with Philadelphia chromosome-positive (PH+) and ABL-class PH-like acute...
- Federal Project Grant Award Summary The National Cancer Institute awarded Baylor College of Medicine a $108,214 Project Grant effective December 1, 2026, through April 16, 2030, under the Cancer Research Manpower program (CFDA 93.398). This award supports research and development activities investigating post-transcriptional regulation as a therapeutic vulnerability in acute myeloid leukemia (AML). The funded research addresses the critical clinical challenge of menin inhibitor resistance, which...